Diving into Data Trends and Ongoing Research in Advanced Endometrial Cancer - Episode 3

Subgroup Data for Lenvatinib/Pembrolizumab In Frontline Advanced Endometrial Cancer After Perioperative Chemo

,

Christian Marth, MD, PhD, and John Chan, MD, discuss subgroup data for frontline lenvatinib/pembrolizumab in endometrial cancer after perioperative chemotherapy.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Current Treatment Strategies and Challenges in Frontline Advanced Endometrial Cancer
    EP. 2: LEAP-001 Data for First-Line Lenvatinib/Pembrolizumab in Advanced Endometrial Cancer
    Now Viewing
    EP. 3: Subgroup Data for Lenvatinib/Pembrolizumab In Frontline Advanced Endometrial Cancer After Perioperative Chemo
    EP. 4: The Role of IO/Chemo Combinations in Frontline Advanced/Recurrent Endometrial Cancer
    EP. 5: ADCs and Novel Agents Under Investigation in Advanced Endometrial Cancer
    EP. 6: Ongoing Research to Watch in Advanced Endometrial Cancer in 2025

    x